Medindia LOGIN REGISTER
Medindia

Artificial Intelligence-enabled Chest Scan Improves Pulmonary Hypertension Diagnosis

by Dr. Jayashree Gopinath on Jun 1 2023 11:05 PM
Listen to this article
0:00/0:00

 Artificial Intelligence-enabled Chest Scan Improves Pulmonary Hypertension Diagnosis
The new feature of Thirona’s AI-based lung quantification platform LungQ™ allows more objective and sensitive quantification of vascular abnormalities from non-contrast CT, with high precision. This in turn helps to detect pulmonary (arterial) hypertension.
It separately identifies the arteries and veins from the scan and accurately quantifies vessel diameters and volumes down to the sub-voxel range, which is crucial to obtain a sensitive and precise analysis.

Primary studies, presented the past week at the ATS 2023 International Conference in Washington, show that AVX allows for non-invasive detection of arterial and venous alterations in the lungs, potentially enabling early diagnosis of P(A)H and differentiating between different vascular disease types such as PH groups (WHO classification).
Novel Artificial Intelligence Framework to Detect Pulmonary Hypertension Precisely The practical implications of the potential of LungQ™ include diagnostic support (1 Trusted Source
Artificial intelligence applied in pulmonary hypertension: a bibliometric analysis

Go to source
), robust measurements of treatment outcomes, and more accurate medical and pharmaceutical research.

LungQ™ AVX does not require a contrast-enhanced CT, its sensitivity and accuracy allow for deep quantification of the pulmonary vasculature in routine CT scans without the need for invasive procedures for the patients.

The insights provided by LungQ™ AVX cannot be subjectively assessed from a CT scan as the eye is not sensitive enough to pick up subtle changes in the dimensions of the pulmonary arteries and veins.

AVX could potentially help PH diagnosis by detecting relevant vascular alterations way earlier than they can be picked up by the current golden standard of hemodynamic measurements by right-heart catheterization.

The expectation is that AV phenotyping will have the most noteworthy benefits in detecting pulmonary hypertension (PH) and its subtypes. PH is a rare disease with a very high underdiagnosis rate.

Advertisement
Applying AI to help with its early detection can potentially result in slowing the disease progression in PH patients by ensuring they get the best possible treatment sooner.

It is an exciting step forward in phenotyping pulmonary vascular disease (2 Trusted Source
A transparent artificial intelligence framework to assess lung disease in pulmonary hypertension

Go to source
). AVX is a result of almost a decade of research and development work aimed at finding vascular phenotypes to improve the diagnosis of a multitude of vascular diseases and to identify new potential therapeutic targets.

Advertisement
Today, we have several validation studies delivering strong evidence that AVX can potentially transform the way we diagnose and treat incurable diseases like pulmonary (arterial) hypertension. And more studies are pending.

References:
  1. Artificial intelligence applied in pulmonary hypertension: a bibliometric analysis - (https://link.springer.com/article/10.1007/s43681-023-00267-8)
  2. A transparent artificial intelligence framework to assess lung disease in pulmonary hypertension - (https://www.nature.com/articles/s41598-023-30503-4)

Source-Medindia


Advertisement